Literature DB >> 173384

Influence of carbon tetrachloride or riboflavin on liver carcinogenesis with a single dose of aflatoxin b1.

J M Scotto, H G Stralin, A Lageron, F J Lemonnier.   

Abstract

Liver carcinogenesis with a single dose of aflatoxin B1 (7 mg/kg body weight) has been investigated in a group of female Wistar strain rats by repeated biopsies and necropsies. Another group received a subsequent intoxication with carbon tetrachloride by inhalation (approximately 200 doses) and another one was overloaded with riboflavin (25 parts/10(6) in drinking water). The frequency of hepatomata was almost equal in the aflatoxin and aflatoxin-carbon tetrachloride group. It was lowere in the riboflavin-aflatoxin group. In these 3 groups cirrhosis was never present in neoplastic livers. Megalocytosis was the first lesion observed. All tumoral livers had previous or concomitant megalocytosis. This modification was about as frequent, intense and widespread in aflatoxin-CCl4 and aflatoxin groups but appeared much earlier, as did the first hepatoma, in the aflatoxin-CCl4 group. It was less frequent, less intense and less widespread in the riboflavin-aflatoxin group than in the aflatoxin group. There was also a lower frequency of hepatomata in the riboflavin-aflatoxin group, but the difference was not significant due to the too small number of animals involved. The facts are not a proof of the existence of an obligatory link between megalocytosis and carcinogenesis since a slight megalocytosis was observed in the riboflavin group not affected by the neoplastic process. However, the simplest explanation of our results would be to consider that the potential tumour cells are located among the megalocytic cells, without admitting that every megalocyte is obligatorily a precancerous cell. CCl4 seems to act in shortening the time of appearance of megalocytosis. The protective effect of riboflavine should be regarded with more caution.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 173384      PMCID: PMC2072738     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  14 in total

1.  [LIGHT MICROSCOPIC STUDIES ON THE EFFECTS OF N-NITROSOMORPHOLINE ON THE LIVER OF RATS AND MICE].

Authors:  P BANNASCH; H A MUELLER
Journal:  Arzneimittelforschung       Date:  1964-07

2.  Induction with carbon tetrachloride of liver-cell carcinomas in hamsters.

Authors:  G DELLA PORTA; B TERRACINI; P SHUBIK
Journal:  J Natl Cancer Inst       Date:  1961-04       Impact factor: 13.506

3.  The portal circulation in experimental cirrhosis of the liver.

Authors:  P M DANIEL; M L PRICHARD; P C REYNELL
Journal:  J Pathol Bacteriol       Date:  1952-01

4.  Ultrastructural and biochemical changes associated with pyrrolizidine-induced hepatic megalocytosis.

Authors:  J R Allen; L A Carstens; D H Norback; P M Loh
Journal:  Cancer Res       Date:  1970-06       Impact factor: 12.701

5.  Riboflavin protection against azo dye hepatoma induction in the rat.

Authors:  J P Lambooy
Journal:  Proc Soc Exp Biol Med       Date:  1970-05

6.  Aflatoxin B1 carcinogenesis in lipotrope-deficient rats.

Authors:  A E Rogers; P M Newberne
Journal:  Cancer Res       Date:  1969-11       Impact factor: 12.701

7.  Regression and persistence of hyperplastic hepatic nodules induced by N-2-Fluorenylacetamide and their relationship to hepatocarcinogenesis.

Authors:  G W Teebor; F F Becker
Journal:  Cancer Res       Date:  1971-01       Impact factor: 12.701

8.  Comparative aspects of aflatoxin-induced hepatic tumors.

Authors:  M C Lancaster
Journal:  Cancer Res       Date:  1968-11       Impact factor: 12.701

9.  Hyperplastic and early neoplastic lesions of the liver in Buffalo strain rats of various ages given subcutaneous carbon tetrachloride.

Authors:  M D Reuber; E L Glover
Journal:  J Natl Cancer Inst       Date:  1967-06       Impact factor: 13.506

10.  [Study of the metabolism of tryptophane in various hepato-intestinal diseases. II. Frequency of anomalies in neoplastic diseases].

Authors:  A Lemonnier; F Lemonnier; B Chevrel; C Charpentier; J Caroli
Journal:  Rev Fr Etud Clin Biol       Date:  1967-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.